PROFESSIONAL EDITION

The largest community of pharma leaders

Regulatory Affairs

      Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time

      BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved ULTOMIRIS® (ravulizumab-cwvz) 100 mg/mL formulation for the treatment...

      AHF Says US Taxpayers Co-own Moderna’s COVID-19 VAX Patent

      WASHINGTON--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) called the recent announcement that Cambridge, Massachusetts-based biotechnology company Moderna has declared that it will not enforce its patent...

      Recent Articles